Cargando…

Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro

Cardiovascular disease has become the primary disease that threatens human health and is considered the leading cause of death. Cardiac remodeling, which is associated with cardiovascular disease, mainly manifests as cardiac hypertrophy, fibrosis, inflammation, and oxidative stress. Farrerol plays a...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Jian, Xu, Dengyue, Wang, Lu, Yu, Xiaohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846078/
https://www.ncbi.nlm.nih.gov/pubmed/36686707
http://dx.doi.org/10.3389/fphar.2022.1079251
_version_ 1784871075010576384
author He, Jian
Xu, Dengyue
Wang, Lu
Yu, Xiaohong
author_facet He, Jian
Xu, Dengyue
Wang, Lu
Yu, Xiaohong
author_sort He, Jian
collection PubMed
description Cardiovascular disease has become the primary disease that threatens human health and is considered the leading cause of death. Cardiac remodeling, which is associated with cardiovascular disease, mainly manifests as cardiac hypertrophy, fibrosis, inflammation, and oxidative stress. Farrerol plays an important role in treating conditions such as inflammation, endothelial injury and tumors, and we speculated that Farrerol may also play an important role in mitigating cardiac hypertrophy and remodeling. We established a model of myocardial remodeling using Angiotensin II (Ang II) with concurrent intraperitoneal injection of Farrerol as an intervention. We used cardiac ultrasound, immunohistochemistry, Immunofluorescence, Wheat Germ Agglutinin, Dihydroethidium, Western Blot, qPCR and other methods to detect the role of Farrerol in cardiac remodeling. The results showed that Farrerol inhibited Ang II-induced cardiac hypertrophy; decreased the ratio of heart weight to tibia length in mice; reduced inflammation, fibrosis, and oxidative stress; and reduced the size of cardiomyocytes in vivo. Farrerol inhibited Ang II-induced cardiomyocyte hypertrophy, levels of oxidative stress, and the proliferation and migration of fibroblast in vitro. Our results revealed that Farrerol could inhibit Ang II-induced cardiac remodeling. Farrerol may therefore be a candidate drug for the treatment of myocardial remodeling.
format Online
Article
Text
id pubmed-9846078
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98460782023-01-19 Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro He, Jian Xu, Dengyue Wang, Lu Yu, Xiaohong Front Pharmacol Pharmacology Cardiovascular disease has become the primary disease that threatens human health and is considered the leading cause of death. Cardiac remodeling, which is associated with cardiovascular disease, mainly manifests as cardiac hypertrophy, fibrosis, inflammation, and oxidative stress. Farrerol plays an important role in treating conditions such as inflammation, endothelial injury and tumors, and we speculated that Farrerol may also play an important role in mitigating cardiac hypertrophy and remodeling. We established a model of myocardial remodeling using Angiotensin II (Ang II) with concurrent intraperitoneal injection of Farrerol as an intervention. We used cardiac ultrasound, immunohistochemistry, Immunofluorescence, Wheat Germ Agglutinin, Dihydroethidium, Western Blot, qPCR and other methods to detect the role of Farrerol in cardiac remodeling. The results showed that Farrerol inhibited Ang II-induced cardiac hypertrophy; decreased the ratio of heart weight to tibia length in mice; reduced inflammation, fibrosis, and oxidative stress; and reduced the size of cardiomyocytes in vivo. Farrerol inhibited Ang II-induced cardiomyocyte hypertrophy, levels of oxidative stress, and the proliferation and migration of fibroblast in vitro. Our results revealed that Farrerol could inhibit Ang II-induced cardiac remodeling. Farrerol may therefore be a candidate drug for the treatment of myocardial remodeling. Frontiers Media S.A. 2023-01-04 /pmc/articles/PMC9846078/ /pubmed/36686707 http://dx.doi.org/10.3389/fphar.2022.1079251 Text en Copyright © 2023 He, Xu, Wang and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
He, Jian
Xu, Dengyue
Wang, Lu
Yu, Xiaohong
Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro
title Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro
title_full Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro
title_fullStr Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro
title_full_unstemmed Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro
title_short Farrerol prevents Angiotensin II-induced cardiac remodeling in vivo and in vitro
title_sort farrerol prevents angiotensin ii-induced cardiac remodeling in vivo and in vitro
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846078/
https://www.ncbi.nlm.nih.gov/pubmed/36686707
http://dx.doi.org/10.3389/fphar.2022.1079251
work_keys_str_mv AT hejian farrerolpreventsangiotensiniiinducedcardiacremodelinginvivoandinvitro
AT xudengyue farrerolpreventsangiotensiniiinducedcardiacremodelinginvivoandinvitro
AT wanglu farrerolpreventsangiotensiniiinducedcardiacremodelinginvivoandinvitro
AT yuxiaohong farrerolpreventsangiotensiniiinducedcardiacremodelinginvivoandinvitro